FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
Portfolio Pulse from Vandana Singh
The FDA has expanded the approval of Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, to include relapsed or refractory mantle cell lymphoma (MCL). This makes Breyanzi the CAR T cell therapy available for the broadest range of B-cell malignancies. The approval is based on positive results from the TRANSCEND NHL 001 trial.
May 31, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA has expanded the approval of Bristol Myers Squibb's Breyanzi to include relapsed or refractory mantle cell lymphoma (MCL). This approval is based on positive trial results and makes Breyanzi the CAR T cell therapy available for the broadest range of B-cell malignancies.
The FDA's expanded approval of Breyanzi for MCL is a significant milestone for Bristol Myers Squibb, as it broadens the therapy's application to the widest range of B-cell malignancies. The positive trial results and the stock's immediate 1.9% increase indicate a positive short-term impact on BMY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100